- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01179945
Effects of a Food Preservative on Glucose Homeostasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Soft drink consumption has been repeatedly implicated in the development of type 2 diabetes (T2DM). Interestingly, epidemiology studies have yielded inconsistent results. Some studies identify sugar-sweetened beverages as the culprit, whereas others point towards artificially-sweetened beverages. Beyond differences in methodology, these conflicting reports raise the question whether another ingredient common to both sugar and artificially-sweetened soft drinks, such as a preservative, might play a role.
Benzoate salts are widely used preservatives in products such as sodas, canned goods, and pharmaceuticals. Interestingly, there is published evidence that sodium benzoate and its metabolite hippurate can affect pancreatic islet function and impair glucose tolerance. However, the effects of oral sodium benzoate at concentrations typically used in our diet on glucose homeostasis have not been systematically studied. Here, we propose to close this knowledge gap.
We will recruit 15 healthy, overweight volunteers, age 18-35. Each subject will receive 4 interventions: an oral glucose challenge 1) with and 2) without 0.1% benzoic acid, and a drink of water 3) with and 4) without 0.1% benzoic acid. Blood samples will be analyzed for glucose, insulin, glucagon, and a panel of approximately 300 different metabolites at baseline and serially for 2 hours after each intervention. Factorial analysis of variance will be performed to determine the effects of benzoic acid in the presence and absence of glucose, and interactions between glucose and benzoate. The planned sample size of 15 will provide 80% power to detect an effect-size of 0.16 standard-deviations in outcome measures, and an interaction-effect of 0.33 standard-deviations, with a critical value p=0.05.
If we find through this study that sodium benzoate significantly affects glucose tolerance, the public health implications would be great. High level, frequent consumption might cause diseases associated with insulin resistance, chiefly T2DM. Furthermore, its presence in OGTT testing solutions could provide misleading results.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital
-
Boston, Massachusetts, United States, 02101
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women age 18-35
- BMI 25-30
Exclusion Criteria:
- Diabetes Mellitus (fasting Blood Glucose ≥ 126mg/dl)
- Exercise more than 60 minutes more that 4 times a week
- Major medical illness
- Medications or supplements that can influence glucose metabolism
- Large fluctuations in weight (>5% over the past 6 months)
- Currently following a weight loss program
- Consumption of more than 24 ounces of soda per day (defined as sugar- or artificially sweetened beverages, e.g. colas or fruit punches, excluding hot tea and coffee)
- Allergy or intolerance to sodium benzoate
- Nicotine use
- Illicit substance use
- Women with irregular menstrual cycles, or who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sodium benzoate containing
|
Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later. Each solution will be consumed over 5 minutes. |
Active Comparator: non sodium benzoate containing
|
Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later. Each solution will be consumed over 5 minutes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose area under the curve (AUC)
Time Frame: 120 minutes post ingestion
|
Plasma glucose will be measured at baseline, 15, 30, 45, 60, 90, and 120 minutes post ingestion of each test solution, and area under the curve will be calculated.
|
120 minutes post ingestion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin AUC
Time Frame: 120 minutes
|
Serum Insulin will be measured at baseline, 15, 30, 45, 60, 90, and 120 minutes post ingestion of each test solution, and area under the curve will be calculated.
|
120 minutes
|
Glucagon AUC
Time Frame: 120 minutes
|
Plasma Glucagon will be measured at baseline, 15, 30, 45, 60, 90, and 120 minutes post ingestion of each test solution, and area under the curve will be calculated.
|
120 minutes
|
Metabolite Profiles
Time Frame: 120 minutes
|
Metabolite analysis will be performed on blood samples at baseline, 15, 30, 45, 60, 90, and 120 minutes post ingestion of each test solution, and area under the curve will be calculated.
|
120 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vamsi Mootha, MD, Massachusetts General Hospital
- Study Director: Belinda S Lennerz, MD, PhD, Boston Children's Hospital
- Study Director: Scott Vafai, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-05-0202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Children's Hospital Los AngelesUniversity of Southern California; Tufts Medical CenterRecruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Khyber Medical University PeshawarRecruitingObesity, OverweightPakistan
-
National Taiwan University HospitalCompleted
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.RecruitingBody Weight | Overweight and ObesityCroatia
Clinical Trials on benzoate containing test drinks
-
DoubleGood ABstarScience GmbHCompletedGlycemic Control | Diet, Food and NutritionSweden
-
Ministry of Health, Saudi ArabiaUnknown
-
Rockefeller UniversityCompletedGlucose Metabolism DisorderUnited States
-
Danone ResearchCompletedUpper Gastric DiscomfortArgentina
-
Imperial College LondonUnknownType 2 Diabetes MellitusUnited Kingdom
-
University of SevilleHospitales Universitarios Virgen del Rocío; Instituto Hispalense de PediatríaCompleted
-
The University of Texas Health Science Center at...Sangi Co., Ltd.CompletedDentin SensitivityUnited States
-
Higher School of Applied Sciences (VIST)European Regional Development Fund; Valens Int. d.o.o., Slovenija; Ministry of...CompletedWrinkles | Skin Hydration | Trans Epidermal Water Loss (TEWL) | Dermis Density | Dermis ThicknessSlovenia
-
Massachusetts General HospitalNutricia North AmericaCompletedAutism | Gastrointestinal SymptomsUnited States
-
Danone ResearchCompleted